Pathological significance and prognostic role of LATS2 in prostate cancer

• Material Type: 博士論文
• Title: Pathological significance and prognostic role of LATS2 in prostate cancer
• Author/Editor: 松田, 剛
• Author Heading: 松田, 剛
• Publication, Distribution, etc.: Wiley Periodicals LLC
• Publication Date: 2022-03-18
• Publication Date (W3CDTF): 2022-03-18
• Alternative Title: 前立腺癌におけるLATS2の病理学的意義と予後予測因子としての役割
• Periodical title: The Prostate
• No. or year of volume/issue: 81 15
• Volume: 81
• Issue: 15
• Pages: 1252-1260
• ISSN (Periodical Title): ISSN : 1097-0045
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2022-03-18
• Dissertation Number: 甲医歯薬第1391号
• Degree Type: 博士(医学)
• Text Language Code: eng
• Subject Heading: biochemical recurrence; malignant aggressiveness; prostate cancer; LATS2; tumorigenesis
• Target Audience: 一般
• Note (General): Background: Large tumor suppressor 2 (LATS2) is an important regulator of the Hippo pathway and it plays crucial roles in cell survival and behaviors. Herein, we evaluated the pathological roles of LATS2 in prostate cancer (PC), for which very little information is available. Methods: Cell proliferation, migration, and invasion in response to the siRNA-mediated knockdown (KD) LATS2 expression were evaluated in two PC cell lines (LNCaP and PC3). The expression of LATS2 in specimens from 204 PC patients was investigated immunohistochemically, and the relationships between its expression and clinicopathological features, proliferation index (PI; measured using an anti-KI-67 antibody), and biochemical recurrence (BCR) were investigated. Results: KD of LATS2 increased the growth, migration, and invasion in LNCaP cells and only increased migration in PC3 cells. The expression of LATS2 was negatively associated with the grade group, T, N, M stage, and PI. In addition, the expression of LATS2 was a useful predictor of the histological effects of neoadjuvant hormonal therapy and BCR-free survival periods. A multivariate analysis model including clinicopathological features showed that negative expression of LATS2 had a significantly higher risk of BCR (odds ratio = 2.95, P < 0.001). Conclusions: LATS2 acts as a tumor suppressor in PC. LATS2 expression is a useful predictor for BCR. LATS2-related activities are possibly dependent on the androgen-dependency of PC cells. Therefore, we suggest that LATS2 could be a potential therapeutic target and a useful predictor for outcome in patients with PC.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1391号 学位授与年月日:令和4年3月18日; Author: Tsuyoshi Matsuda, Yasuyoshi Miyata, Yuichiro Nakamura, Asato Otsubo, Yuta Mukae, Junki Harada, Kensuke Mitsunari, Tomohiro Matsuo, Kojiro Ohba, Bungo Furusato, Hideki Sakai; Citation: The Prostate, 81(15), pp.1252–1260; 2021; identifier:Nagasaki University (長崎大学), 博士(医学) (2022-03-18)
• Source: fulltext; https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27355&item_no=1&attribute_id=70&file_no=1
• Access Restrictions: インターネット公開
• Rights (production): © 2021 The Authors. The Prostate published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
• Related Material: http://hdl.handle.net/10069/00041152
• Related Material (DOI): 10.1002/pros.24226
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 長崎大学 : 長崎大学学術研究成果リポジトリ